Skip to main content
. 2023 Jul 14;2023:6646156. doi: 10.1155/2023/6646156

Table 4.

Clinical data according to the value of platelet-to-monocyte ratio.

Variables Low group (PMR ≤ 118.62, n = 87) High group (PMR > 118.62, n = 242) P
Gender (female/male) 12/75 72/170 0.003
Age (years) 49 (42–59) 51 (45–60) 0.226
WBC (×109/L) 7.09 (4.38–11.01) 3.65 (2.58–5.50) <0.001
Lymphocyte (×109/L) 1.15 (0.61–1.69) 0.84 (0.53–1.37) 0.005
Monocyte (×109/L) 0.71 (0.39–1.17) 0.28 (0.20–0.45) <0.001
Neutrophil (×109/L) 5.24 (3.12–7.75) 2.22 (1.59–3.59) <0.001
Hemoglobin (g/L) 100.05 ± 28.81 102.10 ± 24.49 0.525
PLT (×109/L) 50.0 (31.0–73.0) 66.5 (45.0–119.0) <0.001
Albumin (g/L) 28.75 ± 5.86 31.46 ± 6.11 <0.001
ALT (U/L) 42.9 (20.2–75.5) 28.15 (18.55–58.53) 0.073
AST (U/L) 54.4 (33.8–97.4) 41.7 (28.80–76.08) 0.051
Total bilirubin (μmol/L) 46.10 (23.50–139.40) 25.00 (15.88–48.40) <0.001
Serum creatinine (μmol/L) 69.30 (57.10–95.20) 63.05 (51.75–73.90) 0.001
MELD score 13.37 (9.02–21.74) 8.69 (5.69–12.00) <0.001
INR 1.50 (1.27–1.87) 1.37 (1.24–1.53) <0.001
30-day mortality (yes/no) 17/70 (24.3%) 4/238 (1.7%) <0.001

Data are expressed as number, mean ± standard deviation, or median (interquartile range).